<DOC>
	<DOCNO>NCT02182297</DOCNO>
	<brief_summary>The objective trial investigate safety , tolerability , pharmacokinetics BI 201335 ZW administration single rise dos 40 mg 480 mg BI 201335 NA healthy Japanese male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics BI 201335 NA Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects healthy male volunteer meet criterion : Persons without clinically remarkable finding clinically evident complication base concurrent illness , past medical history , physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , laboratory test result Persons 20 old 35 young Persons body mass index ( BMI ) 18.5 kg/m2 25.0 kg/m2 less Persons willing participate trial study initiation give write consent accordance GCP ( Good Clinical Practice ) Any find medical examination ( include blood pressure , pulse rate , body temperature , ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Prior history jaundice Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior administration trial Use drug within 10 day prior administration trial Participation another trial investigational product within four month prior administration trial Smoker ( &gt; 10 cigarette , &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day ( hospitalisation end trial ) Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A history additional risk factor torsades de pointe ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) The use concomitant medication prolong QT/corrected QT interval</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>